Zerinol gola mint 20 mg - sore throat 18 tablets

Product Description

Composition:

One tablet contains 20 mg of ambroxol hydrochloride. Excipients: sorbitol (1.37 g / lozenge), lactose monohydrate (less than 1 mg per lozenge).

Excipients

Mint flavoring (gum arabic, Chinese mint oil, maltodextrin, lactose monohydrate), sorbitol, sodium saccharin, macrogol 6000, talc.

Therapeutic indications

Symptomatic treatment of pain in acute throat inflammation.

Contraindications

Zerinol Gola Menta 20 mg lozenges is contraindicated in patients with known hypersensitivity to ambroxol or to any of the excipients. Patients with fructose intolerance should not take Zerinol Gola Menta 20 mg lozenges, as they may cause allergic reactions. These contain significant amounts of sorbitol.

Dosage

Adults and children over 12 years: up to 6 lozenges per day, to be dissolved in the mouth. Zerinol Gola Menta 20 mg lozenges should not be used for more than 3 days. If symptoms or high fever persist, the patient should consult a doctor. Zerinol Gola Menta 20 mg lozenges should not be used in children under 12 years of age.

Warnings and precautions

Zerinol Gola Menta 20 mg lozenges should not be used in children under 12 years of age. In very few cases, serious skin lesions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis (TEN), have been observed in conjunction with the administration of expectorants such as ambroxol hydrochloride. Most of these lesions could be explained by the severity of the patient's underlying diseases and/or other concomitant medications. Furthermore, in the early stages of Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN), the patient may initially experience nonspecific, flu-like symptoms, such as fever, muscle aches, rhinitis, cough, and sore throat. Because of these misleading symptoms, symptomatic treatment with cough and cold medications may be initiated. Therefore, if new skin or mucosal lesions occur, consult a doctor immediately and discontinue treatment with ambroxol hydrochloride as a precaution. Episodes of dyspnea may occur in the context of latent disease (e.g., pharyngeal/laryngeal edema). Local allergic reactions (see section 4.8: angioneurotic edema) may also cause dyspnea. The local anesthetic properties of ambroxol may alter sensory perception in the pharyngeal space (see section 4.8: oral and pharyngeal hypoesthesia). Zerinol Gola Menta 20 mg lozenges are not suitable for the treatment of oral ulcers. In such cases, consult your doctor. In case of impaired renal function or severe liver disease, Zerinol Gola Menta 20 mg lozenges should only be used after consulting your doctor. As with any medicine with hepatic metabolism followed by renal elimination, in case of severe renal insufficiency, accumulation of ambroxol metabolites in the liver may occur. This medicine contains 8.2 g of sorbitol per maximum recommended daily dose (1.37 g/lozenge). Patients with rare hereditary conditions of fructose intolerance should not take this medicine. One Zerinol Gola Menta 20 mg lozenge contains less than 1 mg of lactose. This dose does not normally cause problems in lactose-intolerant individuals. However, patients with rare hereditary problems of galactose intolerance, the LAPP lactase deficiency, or glucose-galactose malabsorption problems should use Zerinol Gola mint 20 mg lozenges with caution.

Interactions

No clinically relevant interactions with other drugs have been observed.